TSLA
Tesla
-- 248.710 NVDA
NVIDIA
-- 117.700 PLTR
Palantir
-- 90.960 AAPL
Apple
-- 218.270 MU
Micron Technology
-- 94.720 
NEWS
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, the active ingredient in Ozempic®/Wegovy®, with twice-yearly administration
Study will represent the first clinical application of NanoPortal™, the Company's proprietary drug implant platform technology
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that the Bellberry Human Research Ethics Committee ("HREC") has approved and the Therapeutic Goods Administration ("TGA") in Australia has formally acknowledged a first in human clinical trial of the Company's miniature, subdermal GLP-1 (exenatide) implant in obese and overweight subjects. This clinical trial, known as LIBERATE-1™, will investigate the safety, tolerability and full pharmacokinetic profile of an exenatide implant and represents the first clinical application of the Company's proprietary NanoPortal™ drug implant technology.
Study will represent the first clinical application of NanoPortal™, the Company's proprietary drug implant platform technology
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that the Bellberry Human Research Ethics Committee ("HREC") has approved and the Therapeutic Goods Administration ("TGA") in Australia has formally acknowledged a first in human clinical trial of the Company's miniature, subdermal GLP-1 (exenatide) implant in obese and overweight subjects. This clinical trial, known as LIBERATE-1™, will investigate the safety, tolerability and full pharmacokinetic profile of an exenatide implant and represents the first clinical application of the Company's proprietary NanoPortal™ drug implant technology.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment